Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Chronic and excessive inflammation in skin and joints causes significant morbidity in psoriasis patients. As a prevalent T lymphocyte-mediated disorder, psoriasis, as well as the side effects associated with its treatment, affects patients globally. In this review, recent progress is discussed in the areas of genetics, the immunological synapse, the untangling of the cytokine web and signaling pathways, xenotransplantation models, and the growing use of selectively targeted therapies. Since psoriasis is currently incurable, new management strategies are proposed to replace previous serendipitous approaches. Such strategic transition from serendipity to the use of novel selective agents aimed at defined targets in psoriatic lesions is moving rapidly from research benches to the bedsides of patients with this chronic and debilitating disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The development of psoriatic plaques is accompanied by activation of CD4 + T cells and other immune cells, which provide a plethora of cytokines and chemokines, including TNF and IFNγ 136”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205 · cited 1×
“in keratinocytes to create a “danger signal” is unclear (51), but several possible molecular events may occur to activate resting dendritic APCs (52), followed by delivery of an antigenic signal”
BackgroundPoints of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · cited 1×
“ic inflammatory diseases, HMGB1 is also considered an important regulator (67).”
BackgroundHuman epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183 · cited 10×
“The successful use of cyclosporin, which acts to block cytokine release, resulted in a paradigm shift away from epidermal keratinocytes to various immunocyte populations including T cell subsets and dendritic APCs.”
BackgroundInfluentialAggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
Backgroundp38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Kumar, S., Boehm, J., & Lee, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1177 · Cited by 1,197 · cited 1×
“small molecules that can interfere with inflammatory responses mediated by p38 signaling (106), cytokine receptors (107), or rationally designed dominant negative TNF-α variants (108).”
BackgroundEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
BackgroundWeitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041
Cited by
Items 201–300 of 542
Baker, E. L., Coleman, C. I., Reinhart, K. M., Phung, O. J., Kugelman, L., Chen, W., White, C. M., Mamolo, C. M., Cappelleri, J. C., & Baker, W. L. (2012) · Dermatology and Therapy · doi:10.1007/s13555-012-0009-3 · Cited by 29
“The most common form is plaque psoriasis, which appears as sharply demarcated, erythematous areas covered with silvery-white scale [1, 2].”
BackgroundThe CX3CL1–CX3CR1 system and psoriasis
Plant, D., Young, H. S., Watson, R. E. B., Worthington, J., & Griffiths, C. E. M. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00486.x · Cited by 29
“bacteria) origin, whereupon leucocyte recruitment and activation at the site of the developing cutaneous lesion perpetuates the disease (3).”
BackgroundGriffiths, C. E. M., & Barker, J. N. (2010) · Wiley eBooks · doi:10.1002/9781444317633.ch20 · Cited by 43
Muro, M., Kawakami, H., Matsumoto, Y., Abe, N., Tsuboi, R., & Okubo, Y. (2015) · Journal of Dermatological Treatment · doi:10.3109/09546634.2015.1052036 · Cited by 28
The Differential Regulation of Human ACT1 Isoforms by Hsp90 in IL-17 Signaling
Wu, L., Wang, C., Boisson, B., Misra, S., Rayman, P. A., Finke, J. H., Puel, A., Casanova, J., & Li, X. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400715 · Cited by 29
“characterized by epidermal hyperplasia, aberrant differentiation and hyperproliferation of keratinocytes, and marked infiltration of leukocytes including T cells and neutrophils into the dermis (1, 2).”
BackgroundCan early treatment with biologicals modify the natural history of comorbidities?
Vena, G. A., Vestita, M. G., & Cassano, N. (2010) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2010.01313.x · Cited by 33
Significance of KIR like natural killer cell receptors in autoimmune disorders
Agrawal, S., & Prakash, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108449 · Cited by 28
Wongpiyabovorn, J., Yooyongsatit, S., Ruchusatsawat, K., Avihingsanon, Y., & Hirankarn, N. (2008) · Tissue Antigens · doi:10.1111/j.1399-0039.2008.01134.x · Cited by 27
Interleukin‐20 as a Target in Psoriasis Treatment
Stenderup, K., Rosada, C., Worsaae, A., Clausen, J. T., & Dam, T. N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1423.039 · Cited by 31
Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer
Quatresooz, P., Hermanns‐Lê, T., Pierard, G., Humbert, P. G., Delvenne, P., & Piérard-Franchimont, C. (2012) · BioMed Research International · doi:10.1155/2012/147413 · Cited by 29
Hendriks, A. G. M., Steenbergen, W., Hondebrink, E., van Hespen, J. C. G., van de Kerkhof, P. C. M., & Seyger, M. M. B. (2013) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.777382 · Cited by 27
Sun, W. C., Gao, Y., Yu, X., Yuan, Y., Yi, J., Zhang, Z., Cheng, Y., Li, Y., Peng, X., & Cha, X. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9262 · Cited by 31
“Psoriasis is a common autoimmune disease affecting ~3% of the global population (1).”
Torres‐Álvarez, B., Castanedo-Cázares, J. P., Fuentes‐Ahumada, C., & Moncada, B. (2006) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2006.01916.x · Cited by 27
Increased HIF‐1 alpha immunostaining in psoriasis compared to psoriasiform dermatitides
Ιωάννου, Μ., Sourli, F., Mylonis, I., Barbanis, S., Papamichali, R., Kouvaras, E., Zafiriou, E., Siomou, P., Klimi, E., Simos, G., et al. (2009) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2009.01264.x · Cited by 27
Smajlović, A., Haverić, A., Alić, A., Hadžić, M., Smajlović, A., Mujezinović, İ., Lojo-Kadrić, N., Ramić, J., Elez-Burnjaković, N., Haverić, S., et al. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06445-3 · Cited by 26
Anti-Psoriatic Effect of Rheum palmatum L. and Its Underlying Molecular Mechanisms
Nguyen, L. T. H., Ahn, S. H., Shin, H., & Yang, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416000 · Cited by 30
“Psoriasis is a chronic inflammatory skin disorder characterized by erythematous, thickened, and scaly plaques that can appear on the elbows, knees, scalp or any area of the body surface [1].”
BackgroundThe Expression of p63 during Epidermal Remodeling in Psoriasis
Shen, C.-S., Tsuda, T., Fushiki, S., Mizutani, H., & Yamanishi, K. (2005) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2005.tb00755.x · Cited by 26
Lindwall, G., Hsieh, E. A., Misell, L. M., Chai, C. M., Turner, S., & Hellerstein, M. K. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700189 · Cited by 27
Abe, K., Fuchs, H., Lisse, T. S., Hans, W., & de Angelis, M. H. (2006) · Mammalian Genome · doi:10.1007/s00335-006-0014-x · Cited by 27
“None of psoriasis-susceptibility loci locate to this region (Nickoloff and Nestle 2004), but one of the rheumatoid arthritis-susceptibility loci locates to 1p36 (Cornelis et al. 1998).”
BackgroundThe interleukin-10 family cytokines gene polymorphisms in plaque psoriasis
Kingo, K. (2005) · DSpace repository (University of Tartu) · Cited by 26
Zhao, P., Liu, T., Shi, Y., Li, Z., Shaojie, L., Jia, F., & Chang, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138201 · Cited by 25
Otuki, M. F., Bernardi, C. A., Prudente, A. S., Laskoski, K., Gomig, F., Horinouchi, C. D. D. S., Guimarães, C. L., Ferreira, J., Delle-Monache, F., Filho, V. C., et al. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00689.x · Cited by 25
Redistribution of LRIG Proteins in Psoriasis
Karlsson, T., Mark, E. B., Henriksson, R., & Hedman, H. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701175 · Cited by 26
“The immunological component of the disease is clearly important (Nickoloff and Nestle, 2004); however, dysregulated growth factor signaling has also been implicated.”
BackgroundEfalizumab, a reversible T-cell modulator for psoriasis
Shear, N. H., Langley, R. G. B., & HO, V. C. (2005) · Journal of Cutaneous Medicine and Surgery · doi:10.1007/s10227-006-0101-3 · Cited by 25
Frers, R. A. K., Bisoendial, R. J., Montoya, S., Kerzkerg, E., Castilla, R., Tak, P. P., Milei, J., & Capani, F. (2015) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2015.01.005 · Cited by 24
“IL-23 stimulates the secretion of IL-22 by Th17 cells, which may be involved in epidermal hyperplasia [5].”
BackgroundPoliti, F. A. S., Carvalho, S. G., Rodero, C. F., Santos, K. P., Meneguin, A. B., Sorrechia, R., Chiavacci, L. A., & Chorilli, M. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.147 · Cited by 25
Immune-Regulatory Mechanisms in Systemic Autoimmune and Rheumatic Diseases
Takakubo, Y., & Konttinen, Y. T. (2011) · Clinical and Developmental Immunology · doi:10.1155/2012/941346 · Cited by 29
“Psoriasis is a common chronic inflammatory disease of the skin in which the local activation of autoimmune DCs and T cells induces an abnormal differentiation of epidermal keratinocytes [111, 112].”
BackgroundLiu, R. F., Wang, F., Wang, Q., Zhao, X., & Zhang, K. M. (2015) · Genetics and Molecular Research · doi:10.4238/2015.december.21.49 · Cited by 28
Psoriasis for the primary care practitioner
Young, M. S., Aldredge, L. M., & Parker, P. A. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12443 · Cited by 31
Zerria, K., Jerbi, E., Hammami, S., Maaroufi, A., Boubaker, S., Xiong, J. P., Arnaout, M. A., & Fathallah, D. M. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02454.x · Cited by 24
Watabe, D., Kanno, H., Yoshida, A., Kurose, A., Akasaka, T., & Sawai, T. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08039.x · Cited by 26
Transcription factors in autoimmune diseases
Stanford, L. P. (2008) · Frontiers in bioscience · doi:10.2741/3001 · Cited by 23
Psoriatic arthritis therapy advances
Mease, P. J. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000166382.96024.85 · Cited by 24
Eliasson, L., Bewley, A., Mughal, F., Johnston, K., Kuznik, A., Patel, C., & Lloyd, A. J. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s121838 · Cited by 23
“Treatment options have expanded significantly in recent years, with conventional systemic oral therapies such as methotrexate and a range of effective injectable biologic options, including antitumor necrosis factor-α, anti-interleukin 12/23, and anti-interleukin 17 agents, now available to patients with moderate-to-s…”
Perceived impact of psoriasis on leisure-time activities
Leino, M., Mustonen, A., Mattila, K., Koulu, L. M., & Tuominen, R. J. (2014) · European Journal of Dermatology · doi:10.1684/ejd.2014.2282 · Cited by 23
Effects of Expression of Transcriptional Factor AP-1 FOSL1 Gene on Psoriatic Process
Соболев, В. В., Zolotorenko, A. D., Соболева, А. Г., Elkin, A. M., Ильина, С. А., Николаевич, С. Д., Потекаев, Н. Н., Тkachenko, S. B., Minnibaev, M. T., & Львович, П. А. (2011) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-011-1208-0 · Cited by 25
Ayroldi, E., Bastianelli, A., Cannarile, L., Petrillo, M. G., Delfino, D. V., & Fierabracci, A. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798157649 · Cited by 26
“For example, IL-18, IL-19, IL-22, and IL-23 have been described as mediators of inflammatory psoriatic lesions [74].”
BackgroundShih, C., Huang, C., Wang, K.-H., Huang, C., Wei, P., Chang, Y., Hsieh, C.-K., Liu, K.-T., & Lee, A.-W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092610 · Cited by 22
“Psoriasis affects the skin, nails, and, sporadically, the joints and is characterized by epidermal hyperproliferation, abnormal differentiation of keratinocytes, and lymphocyte infiltration, which results in the raised plaques that constantly molt scales originating from excessive growth of the epidermal skin layer [3…”
BackgroundIn Vivo and In Vitro Models of Psoriasis
Jean, J., & Pouliot, R. (2010) · InTech eBooks · doi:10.5772/8582 · Cited by 22
“2 Psoriasis Epidemiology Psoriasis is an ancient chronic skin disease (Nickoloff and Nestle, 2004).”
InfluentialRecombinant Murine Interleukin 4 Protein Therapy for Psoriasis in a Transgenic VEGF Mouse Model
Ren, X., Li, J., Zhou, X., Luo, X., Huang, N., Wang, Y., Chen, X., & Wei, Y. (2009) · Dermatology · doi:10.1159/000235974 · Cited by 22
Copy number variations in IL22 gene are associated with Psoriasis vulgaris
Prans, E., Kingo, K., Traks, T., Silm, H., Vasar, E., & Kõks, S. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.01.006 · Cited by 23
Nestle, F. O., & Conrad, C. (2004) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2004.11.005 · Cited by 22
Self-citationCTLA‐4 gene polymorphisms and natural soluble CTLA‐4 protein in psoriasis vulgaris
Łuszczek, W., Kubicka, W., Jasek, M., Baran, E., Cisło, M., Nockowski, P., Łuczywo‐Rudy, M., Wiśniewski, A., Nowak, I., & Kuśnierczyk, P. (2006) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2006.00600.x · Cited by 22
The caspase‐cleaved form of LYN mediates a psoriasis‐like inflammatory syndrome in mice
Marchetti, S., Gamas, P., Belhacène, N., Grosso, S., Pradelli, L. A., Colosetti, P., Johansen, C., Iversen, L., Deckert, M., Luciano, F., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.183 · Cited by 25
“To validate the clinical relevance of LynDN mice as a new model for psoriasis, we treated them with etanercept, a leading agent used for treating patients with psoriasis (Nickoloff and Nestle, 2004).”
MethodKhawaja, A. R., Bokhari, S. M. A., Rasheed, T., Shahzad, A., Hanif, M., Qadeer, F., & Jafferany, M. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01629 · Cited by 29
Etiopathogenesis of Psoriasis from Genetic Perspective: An updated Review
Torkamandi, S., Mikaeili, H., Sahebkar, A., Babaie, F., Omraninava, M., Gorabi, A. M., Khosrojerdi, A., Aslani, S., Yazdchi, A., & Sathyapalan, T. (2022) · Current Genomics · doi:10.2174/1389202923666220527111037 · Cited by 30
“com cells and the development of psoriatic-plaques [2, 4].”
BackgroundThe Experimental Animal Models in Psoriasis Research: A Comprehensive Review
Parab, S. B., & Doshi, G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109897 · Cited by 23
Bergman, R. N., Ramón, M., Wildbaum, G., Avitan‐Hersh, E., Mayer, E., Shemer, A., & Karin, N. (2009) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2009.08.006 · Cited by 21
“Psoriasis is a chronic, immunologically based inflammatory skin disease in which cytokines and chemokines released from cutaneous antigen-presenting cells, T cells and keratinocytes are believed to play a key role [1,2].”
BackgroundResultIntervention Strategies and Agents Mediating the Prevention of Xenorejection
Ghebremariam, Y. T., Smith, S. A., Anderson, J. B., Kahn, D. R., & Kotwal, G. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1352.028 · Cited by 21
Gatzka, M., Hainzl, A., Peters, T., Singh, K., Tasdogan, A., Wlaschek, M., & Scharffetter‐Kochanek, K. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300976 · Cited by 20
Analysis of perforin expression in peripheral blood and lesions in severe and mild psoriasis
Massari, L. P., Kaštelan, M., Laškarin, G., Zamolo, G., Massari, D., & Rukavina, D. (2007) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2007.02.007 · Cited by 21
“Brow seems that T cells are responsible for initiation and maintenance of psoriatic plaque [16].”
BackgroundStudy on Certain Biomarkers of Inflammation in Psoriasis Through “OMICS” Platforms
Rodríguez‐Cerdeira, C., Molares-Vila, A., Sánchez-Blanco, E., & Sánchez-Blanco, B. (2014) · The Open Biochemistry Journal · doi:10.2174/1874091x01408010021 · Cited by 21
Yadav, K., Singh, D., Singh, M. R., Minz, S., Gnanakani, S. P. E., Sucheta, Yadav, R., Vora, L. K., Sahu, K. K., Bagchi, A., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109945 · Cited by 22
The Pathophysiology of Psoriasis
Hugh, J. M., Newman, M. D., & Weinberg, J. M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4432-8_2 · Cited by 22
Noninvasive approach for enhancing small interfering RNA delivery percutaneously
Aljuffali, I. A., Lin, Y., & Fang, J. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1121988 · Cited by 20
“[42] TNF-α is a pro-inflammatory cytokine that is upregulated in psoriatic lesions.”
BackgroundSrivastava, A., Nagar, H. K., Chandel, H., & Ranawat, M. S. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.190740 · Cited by 20
“[1] Psoriasis is a lifelong disorder with unpredictable remissions and relapse affecting the psychosocial life of the patients.[2] Although genetic, immunological, and environmental factors seem to be implicated, the exact cause is not yet known, and even today, psoriasis is a serious global problem.”
BackgroundAutoimmune Disorders – Immunopathogenesis and Potential Therapies
Ganapathy, S., Vedam, V., Rajeev, V., & Arunachalam, R. (2017) · Journal of Young Pharmacists · doi:10.5530/jyp.2017.9.4 · Cited by 27
Alshenawy, H. A., & Hasby, E. A. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2011.03.015 · Cited by 20
Sticherling, M. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.05.019 · Cited by 20
Genes and structure of selected cytokines involved in pathogenesis of psoriasis.
Pietrzak, A., Zalewska-Janowska, A. M., Chodorowska, G., Nockowski, P., Michalak-Stoma, A., Osemlak, P., & Krasowska, D. (2008) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-008-0002-y · Cited by 21
Advancing insights into psoriasis: from pathogenesis to current and emerging therapies
Gonçalves, M. B. S., Fonseca, M., Mascarenhas‐Melo, F., & Figueiras, A. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115429 · Cited by 29
IL-10 implications in psoriasis.
Robaee, A. A. A., Alzolibani, A. A., Al-Shobili, H. A., Kazamel, A., & Settin, A. (2008) · Europe PMC (PubMed Central) · Cited by 19
Wang, H., von Rohrscheidt, J., Röhrbein, J. H., Peters, T., Sindrilaru, A., Keß, D., Preissner, K. T., & Scharffetter‐Kochanek, K. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.310 · Cited by 19
“…of psoriasis is supported by several lines of evidence including the fact that psoriasis can be induced in severe combined immunodeficient mouse xenograft model by injection of T cells or immunocytes from psoriasis patients (Schon et al., 1997; Nickoloff and Nestle, 2004; Sano et al., 2005).”
BackgroundInfluentialThe therapeutic potential of TNF-α antagonists for skin psoriasis comorbidities
Pierard, G., Piérard-Franchimont, C., Szepetiuk, G., Paquet, P., & Quatresooz, P. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.500283 · Cited by 22
“A cluster of these adipokines is represented by proinflammatory mediators, such as TNF-a, IL-6 and IL-8, whose overproduction drives the pathogenesis and activity of psoriasis, as well as of some basic features of metabolic syndrome like insulin resistance and diabetes [17,52,53].”
BackgroundDutkiewicz, E. P., Hsieh, K.-T., Urban, P. L., & Chiu, H. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa009 · Cited by 21
The Model of PPARγ -Downregulated Signaling in Psoriasis
Соболев, В. В., Nesterova, A. P., Соболева, А. Г., Dvoriankova, E., Львович, П. А., Руслановна, М. Д., Korsunskaya, I. M., & Свитич, О. А. (2020) · PPAR Research · doi:10.1155/2020/6529057 · Cited by 20
“Multiple genes cause heterogeneous heredity of psoriasis [1, 2].”
BackgroundCD18 in Monogenic and Polygenic Inflammatory Processes of the Skin
Peters, T., Sindrilaru, A., Wang, H., Oreshkova, T., Renkl, A. C., Keß, D., & Scharffetter‐Kochanek, K. (2006) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650006 · Cited by 22
“Different cell types have been suspected to be the primary inducer in the pathogenesis of psoriasis (van den Oord and de Wolf-Peeters, 1994; Nickoloff, 1999; Nickoloff and Nestle, 2004; Ozawa and Aiba, 2004).”
BackgroundSanchez, A. P. G. (2010) · Anais Brasileiros de Dermatologia · doi:10.1590/s0365-05962010000500028 · Cited by 19
Bonnekoh, B., Böckelmann, R., Pommer, A. J., Malykh, Y. N., Philipsen, L., & Gollnick, H. P. M. (2006) · Skin Pharmacology and Physiology · doi:10.1159/000097982 · Cited by 19
Psoralen-ultraviolet a treatment with Psoralen-ultraviolet B therapy in the treatment of psoriasis
Asim, S. A., Ahmed, S., & Us-Sehar, N. (2013) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.293.2622 · Cited by 19
“Erythema 7(28) 6(24) Pruritis 8(32) 7(28) Nausea, vomiting 7(28) 6(24) Fever & malaise 4(16) 3(12) Headache 3(12) 4(16) Blister 1(4) 0(0) Claustrophobia 1(4) 0(0)”
Adibi, N., & ROBATI, R. M. (2021) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_585_20 · Cited by 20
Lv, J., Wang, Y., Xu, J., Zhou, T., Chen, Z., Yang, H., Di, T., & Li, P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112604 · Cited by 18
Zhang, K., Li, X., Yin, G., Liu, Y., & Tang, X. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.01016.x · Cited by 18
Wang, H., Keß, D., Lindqvist, A.-K., Peters, T., Sindrilaru, A., Wlaschek, M., Blakytny, R., Holmdahl, R., & Scharffetter‐Kochanek, K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5520 · Cited by 17
“Different cell types have been proposed to be the primary triggers in the pathogenesis of psoriasis (2), with T cells being essential for its initiation (5–7), whereas macrophages maintain its inflammatory state (8, 9).”
BackgroundRashed, L. A., Hay, R. M. A., Mahmoud, R. H., Hasan, N., Zahra, A. A., & Fayez, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132915 · Cited by 18
“ACE has been also reported to degrade SP that promotes vasodilation, it also upregulates ICAM-1 expression in the endothelial cells, and promotes the expression of inflammatory cytokines such as IL-6 and IL-8 [33].”
BackgroundLe TNF-δ dans la physiopathologie du psoriasis
Rozières, A., Hennino, A., & Nicolas, J. (2006) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(06)70873-0 · Cited by 19
“Au niveau cutané, le TNF-α est produit par de nombreux types cellulaires comme les kératinocytes, les lymphocytes, les fibroblastes, les monocytes et les cellules dendritiques [2, 27].”
BackgroundInfluentialPerera, R. J., Koo, S., Bennett, C. F., Dean, N. M., Gupta, N., Qin, J., & Nickoloff, B. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20785 · Cited by 20
“Inappropriate induction of cell death (e.g., premature cell death), or alterations in the differentiation process adversely influences barrier function and enhances susceptibility to infection, thereby contributing to a wide spectrum of skin diseases, including graft-versushost disease, toxic epidermal necrolysis, pso…”
Self-citationde Kruijf, P., Lim, H. D., Overbeek, S. A., Zaman, G. J. R., Kraneveld, A. D., Folkerts, G., Leurs, R., & Smit, M. J. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.06.017 · Cited by 18
“Subsequently, this will lead to increased tissue damage and thereby enhanced clinical symptoms of inflammatory diseases like chronic obstructive pulmonary disease, inflammatory bowel disease and psoriasis (Barnes, 2007; Chin and Parkos, 2006; Nickoloff and Nestle, 2004; Viola and Luster, 2008).”
BackgroundOccurrence of Plantar Pustular Psoriasis during Treatment with Infliximab
English, P. L., & Vender, R. B. (2009) · Journal of Cutaneous Medicine and Surgery · doi:10.2310/7750.2008.07080 · Cited by 17
“P SORIASIS is a T lymphocyte–mediated disorder of unknown cause affecting approximately 2 to 3% of the population worldwide.(1) Psoriasis is characterized by sharply demarcated, erythematous, squamous lesions.”
BackgroundReddy, K. R., Satyanarayana, S. V., & Reddy, V. (2019) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2019v11i5.33592 · Cited by 17
“All these events further progress to mark hyperkeratosis, congealing of epidermis and neovascularization [5].”
BackgroundBharatha, M., Nandana, M. B., Praveen, R., Nayaka, S., Velmurugan, D., Vishwanath, B. S., & Rajaiah, R. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111679 · Cited by 18
Lemini-López, A., Flores‐Romo, L., Arévalo-López, A., & Meza, I. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.07.003 · Cited by 17
Investigation of Anti-Inflammatory Potential of N-Arylcinnamamide Derivatives
Hošek, J., Kos, J., Strhársky, T., Černá, L., Štarha, P., Vančo, J., Trávnı́ček, Z., Devı́nsky, F., & Jampílek, J. (2019) · Molecules · doi:10.3390/molecules24244531 · Cited by 17
“Chronic inflammation is a hallmark of many diseases, including atherosclerosis [2], rheumatoid arthritis [3], psoriasis [4], cancer [5], chronic respiratory diseases [6,7], and type 2 diabetes mellitus [8].”
BackgroundAntipsoriatic activity of extracts and fractions obtained fromMemecylon malabaricumleaves
Dhanabal, S. P., Nithyanantham, M., Basavaraj, K. H., Wadhwani, A., & Shamasundar, N. M. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01528.x · Cited by 17
Animal models of psoriasis and psoriatic arthritis: An update
Conrad, C., & Nestle, F. O. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0063-x · Cited by 18
Self-citationAyala, F., Lambert, J., & on Behalf of the TANGO Study Group (2014) · Journal of Dermatological Treatment · doi:10.3109/09546634.2014.952611 · Cited by 16
“immunological basis of psoriasis has led to new therapeutic approaches targeting pathogenic inflammatory processes (5,6).”
BackgroundFrom bench to bedside – translational research in psoriasis
Prinz, J. C. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03829.x · Cited by 16
Just, H., Deleuran, M. S., Vestergaard, C., Deleuran, B. W., & Thestrup‐Pedersen, K. (2008) · Acta Dermato Venereologica · doi:10.2340/00015555-0550 · Cited by 16
“Apart from their role in AD, T cells play a major role in the pathogenesis of psoriasis (7).”
BackgroundElneam, A. I. A., Al‐Dhubaibi, M. S., & Alrheam, A. I. A. A. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.188 · Cited by 16
“Also, inactivation of bradykinin by ACE stimulates the synthesis of cytokines such as IL-6, IL-8 and nitric oxide (NO) [8] [9] [10].”
BackgroundBeck, K., Sanchez, I. M., Yang, E., & Liao, W. J. (2018) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s146640 · Cited by 16
“The development of targeted biologic therapies as a systemic treatment option for psoriasis is a result of advances in the understanding of the immune-mediated pathophysiology of psoriasis over the past 20 years.(4) Currently, biologic medications approved for the treatment of plaque psoriasis include tumor necrosis f…”
BackgroundDesign and synthesis of the 4H-chromenone derivatives against psoriasis
Zhang, F., Yan, Y., Han, X., Du, J. C., Zhu, R., & Liu, X. H. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105640 · Cited by 15
Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience
Budamakuntla, L., Madaiah, M., Sarvajnamurthy, S., & Kapanigowda, S. (2014) · Clinical and Experimental Dermatology · doi:10.1111/ced.12509 · Cited by 15
Apoptosis mediated by cytolytic molecules might be responsible for maintenance of psoriatic plaques
Kaštelan, M., Massari, L. P., & Brajac, I. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.01.051 · Cited by 15
He, Y., Zhang, Y., Lu, J., & Lin, R. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.03.007 · Cited by 15
Takuathung, M. N., Wongnoppavich, A., Pitchakarn, P., Panthong, A., Khonsung, P., Chiranthanut, N., Soonthornchareonnon, N., & Sireeratawong, S. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/5906539 · Cited by 15
“Extensive evidence has shown the involvement and role of T cells with a mixed proinflammatory Th1/Th17 cytokine in pathogenesis of psoriasis through causing inflammation, neovascularization, and hyperproliferation of keratinocytes [25, 26].”
BackgroundApplications of the 308-nm excimer laser in dermatology
Farkas, Á., & Kemény, L. V. (2006) · Laser Physics · doi:10.1134/s1054660x06050203 · Cited by 15
Efalizumab: continuous therapy for chronic psoriasis
Cather, J. C., & Menter, A. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.3.393 · Cited by 15
“The need for therapies that are both effective and safe for long-term continuous use, together with advances in our understanding of the immunopathogenesis of psoriasis, have led to the development of new biological therapies with more selective mechanisms of action that are likely to be associated with improved safet…”
BackgroundTargeting the Interleukin-12/23 Cytokine Family in the Treatment of Psoriatic Disease
Shear, N. H., Prinz, J. C., Papp, K. A., Langley, R. G. B., & Gulliver, W. P. (2008) · Journal of Cutaneous Medicine and Surgery · doi:10.2310/7750.2008/08070 · Cited by 14
Yang, C., Chen, M., Huang, H., Li, X., Qian, D., Hong, X., Zheng, L., Hong, J., Hong, J., Zhu, Z., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.07.692 · Cited by 18
Aydin, A. F., Develi-İş, S., Doğru‐Abbasoğlu, S., Vural, P., Özderya, A., Karadağ, B., & Uysal, M. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.11.017 · Cited by 14
“EDN1 regulates angiogenesis and many autoimmunemechanisms by promoting the migration and proliferation of endothelial cells, stimulating leukocyte adhesion to the endothelium, and initiating monocyte/macrophage chemotaxis [22,23].”
Background
Metadata
- Authors
- Nickoloff, B. J., & Nestle, F. O.
- Affiliations
- Loyola University Medical Center (US)
- University of Zurich (CH)
- Corresponding author
- Nickoloff, Brian J.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-06-15
- Volume
- 113
- Issue
- 12
- Pages
- 1664-1675
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC420513
- OpenAlex
- W2024387258
- Cited by
- 544
- References
- 110
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 18 · 2020: 10 · 2019: 23 · 2018: 18 · 2017: 17 · 2016: 19 · 2015: 24 · 2014: 26 · 2013: 29 · 2012: 27
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Doris Duke Charitable Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR40065, R01AR040065)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- psoriasis, immunopathogenesis, T cells, immunological synapse, cytokine signaling pathways, xenotransplantation model, targeted therapy, psoriasis genetics, chronic skin inflammation, psoriatic arthritis
- MeSH terms
- Animals, Dermatologic Agents, Disease Models, Animal, Disease Susceptibility, Humans, Immune System, Psoriasis, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.